Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

3 treatments under study, led by Alefacept

Related Conditions

Often studied with 14 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 2/3 (1)

Trial Status

Terminated1
Completed1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT03984890Phase 2/3Completed

Vitamin D3 For CGD Patients With BCGosis/Itis

NCT01319851Not ApplicableTerminated

Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation

Showing all 2 trials

Research Network

Common Treatments

  • Alefacept1
  • Cholecalciferol1
  • Traditional Treatment Of Cgd And Tb1

Active Sponsors

  • Children's Hospital of Fudan University1
  • Children's Healthcare of Atlanta1
  • Emory University1

Top Investigators

Related Conditions

  • Leukocyte Adhesion Deficiency1
  • Fanconi Anemia1
  • Severe Congenital Neutropenia1
  • Dyskeratosiscongenita1
  • Glanzmann Thrombasthenia1

Activity Timeline